S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.59 (-1.85%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.59 (-1.85%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.59 (-1.85%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.59 (-1.85%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
Free Trial
NASDAQ:PTI

Proteostasis Therapeutics (PTI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PTI Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.41
▼
$0.55
50-Day Range
$1.00
▼
$22.42
52-Week Range
$0.87
▼
$2.72
Volume
848,743 shs
Average Volume
1.04 million shs
Market Capitalization
$25.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
PTI stock logo

About Proteostasis Therapeutics Stock (NASDAQ:PTI)

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

PTI Stock News Headlines

July 20, 2023 | bizjournals.com
Greensboro joins incentive offers for $55M Honda expansion at PTI; Guilford County up next
March 13, 2023 | bloomberg.com
Federal Police Summons India Minister in Bribery Probe, PTI Says
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 6, 2022 | nj.com
7 years later, probation and PTI for pair in North Bergen low-show/no-show job scheme
October 26, 2021 | finance.yahoo.com
Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
See More Headlines
Receive PTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTI
CUSIP
N/A
CIK
1445283
Web
www.proteostasis.com
Phone
617-225-0096
Fax
N/A
Employees
44
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,130,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.39%
Return on Assets
-55.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.69
Quick Ratio
6.69

Sales & Book Value

Annual Sales
$5 million
Price / Sales
5.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.22 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
52,185,000
Free Float
N/A
Market Cap
$25.37 million
Optionable
Not Optionable
Beta
1.16
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ms. Meenu Chhabra (Age 48)
    Pres, CEO & Director
    Comp: $844.78k
  • Dr. Marija Zecevic (Age 46)
    Chief Commercial Officer
    Comp: $530.46k
  • Michael L. Alfieri
    Head of Fin.
  • Dr. Benito Munoz (Age 58)
    Chief Scientific Officer
  • Ms. Janet L. Smart Esq. (Age 63)
    Ph.D., J.D., Sr. VP of Legal Affairs
  • Dr. Geoffrey S. Gilmartin (Age 52)
    Chief Medical Officer
  • Ms. Claudia Styslinger
    Investor Relations Exec.

Key Competitors

View All Competitors

PTI Stock Analysis - Frequently Asked Questions

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) posted its earnings results on Monday, November, 16th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01.

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST).

When did Proteostasis Therapeutics IPO?

Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

This page (NASDAQ:PTI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
My biggest AI fear
Paradigm Press